Twin Capital Management Inc. purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 4,075 shares of the life sciences company’s stock, valued at approximately $812,000.

A number of other large investors also recently made changes to their positions in ILMN. Winslow Capital Management LLC bought a new stake in Illumina in the second quarter valued at $211,584,000. HPM Partners LLC grew its position in Illumina by 29,103.8% in the second quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock valued at $107,724,000 after acquiring an additional 749,424 shares during the period. Fred Alger Management Inc. grew its position in Illumina by 611.9% in the second quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock valued at $110,636,000 after acquiring an additional 548,030 shares during the period. TIAA CREF Investment Management LLC grew its position in Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after acquiring an additional 527,548 shares during the period. Finally, Capital World Investors grew its position in Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after acquiring an additional 410,000 shares during the period. Hedge funds and other institutional investors own 91.76% of the company’s stock.

Illumina, Inc. (NASDAQ:ILMN) opened at $225.24 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. The company has a market capitalization of $33,584.38, a price-to-earnings ratio of 67.26, a price-to-earnings-growth ratio of 3.80 and a beta of 0.79. Illumina, Inc. has a one year low of $119.37 and a one year high of $230.72.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same quarter in the prior year, the firm posted $0.97 earnings per share. The firm’s revenue for the quarter was up 17.6% compared to the same quarter last year. sell-side analysts expect that Illumina, Inc. will post 3.75 EPS for the current year.

In other news, EVP Marc Stapley sold 2,000 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $205.93, for a total transaction of $411,860.00. Following the transaction, the executive vice president now owns 36,179 shares of the company’s stock, valued at $7,450,341.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $205.71, for a total value of $29,827.95. The disclosure for this sale can be found here. Insiders have sold 161,360 shares of company stock worth $33,599,137 in the last ninety days. 0.89% of the stock is currently owned by insiders.

A number of brokerages have weighed in on ILMN. BidaskClub cut Illumina from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Canaccord Genuity reiterated a “buy” rating and issued a $230.00 price target (up from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Goldman Sachs Group reiterated a “neutral” rating and issued a $200.00 price target on shares of Illumina in a research report on Tuesday, September 26th. Finally, Janney Montgomery Scott raised Illumina from a “sell” rating to a “neutral” rating in a research note on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the stock. Illumina presently has an average rating of “Hold” and an average price target of $200.88.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/twin-capital-management-inc-purchases-shares-of-4075-illumina-inc-ilmn/1738528.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.